CorEvitas is now enrolling qualified sites for the Alopecia Areata Registry. If you are interested in participating, we invite you to complete a brief feasibility survey.
Alopecia Areata is an autoimmune disease caused by genetic and environmental factors, that result in non-scarring hair loss, as inflammatory pathways destroy hair follicles. It currently afflicts approximately two out of every 1,000 people in the U.S. and over 100 million people worldwide. Novel and effective therapies for Alopecia Areata offer patients the promise of effective treatment and relief from the burden of the disease, and a vastly improved quality of life.
The Alopecia Areata (AA) Registry, is a prospective, observational cohort study for subjects with AA under the care of a dermatology provider. A first of its kind in Alopecia Areata, the registry is designed to study the natural history of AA, the real-world effectiveness and safety of medications used in the treatment of AA, and drug utilization treatment patterns.
Read the Press Release, here.
Associate Professor of Dermatology, Yale University School of Medicine | Clinician, Yale Dermatology-Middlebury
Assistant Professor of Dermatology Harvard Medical School | Director, Lahey Hair Loss Center of Excellence & Hair Academic Innovative Research Unit, Beth Israel Lahey Health | Board of directors, Cicatricial Alopecia Research Foundation and American Hair Research Society
